TY - JOUR T1 - Highlights from this issue JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 1 LP - 1 DO - 10.1136/bjophthalmol-2014-305599 VL - 98 IS - 7 AU - Keith Barton AU - James Chodosh AU - Jost B Jonas Y1 - 2014/07/01 UR - http://bjo.bmj.com/content/98/7/1.abstract N2 - Wykoff and colleagues determined whether 2.0 mg intravitreal aflibercept as therapy for exudative age-related macular degeneration could maintain or even improve upon the visual acuity and anatomic gains of the Super-dose Anti-VEGF (SAVE) Trial in patients who had received 2.0 mg intravitreal ranibizumab for recalcitrant exudative age-related macular degeneration.1 The study included 46 patients with a mean of 42 prior intravitreal treatments. At 6 months after baseline, BCVA had not changed significantly (P=0.71), while central subfield thickness had improved significantly. At 6 months after baseline, ten of 45 (22%) patients had no retinal fluid and no patient lost >15 letters. The authors conclude that aflibercept 2.0 mg treatment maintained the improvements in visual acuity previously achieved with high-dose 2.0-mg ranibizumab injections in patients with recalcitrant wet age-related macular degeneration. In a retrospective clinical-histopathological case series study, Rootman and colleagues examined … ER -